Identifying human epidermal growth factor receptor 2 (HER2), elucidating its intracellular signaling mechanisms in tumor cells, and the advent of the recombinant anti-HER2 monoclonal antibody trastuzumab led to a transformative change in oncology research. The gene discussed is ERBB2; the disease is neoplasm.